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Abstract
Background: Malaria is a major public health problem in French Guiana, where Plasmodium vivax
has become the dominant malaria species since 2000. As in others endemic areas, it is important
to specify the pattern of vivax malaria relapses and to try to discriminate efficiently re-infections
from relapses.
Methods: This study was conducted in children born between January 1, 2001 and December 31,
2008 in Camopi, an Amerindian village located in the Amazon forest (n = 325), using an open
cohort design. Primary and secondary attack rates of P. vivax were calculated using survival analysis.
With the difference between the primary and secondary rates, this study aimed to estimate
indirectly P. vivax relapse rate and evaluate its time evolution.
Results: Of the 1042 malaria attacks recorded, 689 (66%) were due to P. vivax (without mixed
infection). One hundred and fifty one children had their primary attack with P. vivax and 106 had
their two first attacks with P. vivax. In the absence of primaquine treatment, it was shown that P.
vivax relapses mainly occurred during the first three months after the first attack. Thirty percent of
children never had a relapse, 42% had a relapse before the first month after primary attack, 59%
before the second month and 63% before the third month.
Conclusion: This study confirmed that the relapse pattern in Camopi was compatible with the
pattern described for the P. vivax Chesson (tropical) strain. In addition, due to the relapse rate time
evolution, a simple arbitrary classification rule could be constructed: before 90 days after the
primary attack, the secondary attack is a relapse; after 90 days, it is a re-infection. Adapted
management of malaria cases based on these results could be devised.
Background
Traditionally, Plasmodium vivax was considered as a rela-
tively benign malaria parasite, which could be easily
treated. For the past 10 years, this has been questioned [1].
It has been shown that malaria could be involved in
severe disease [2]. Furthermore, P. vivax has recently re-
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emerged [3] and drug resistances, mainly chloroquino-
resistance have developed in several areas[4]. Primaquine
treatment, the only therapeutic option against relapse,
might also be failing [5]. It requires a 14-day course and
G6PD deficiency screening, which is difficult and costly in
some areas.
In French Guiana, P. vivax has become the dominant
malaria species since 2000, with more than 60% of
malaria attacks [6]. Knowledge about its relapse pattern is
limited. Plasmodium falciparum remains predominant on
the Maroni River, where the maroon populations are
mostly Duffy negative and, therefore, resistant to P. vivax.
Plasmodium malariae has been observed in 2% of malaria
cases.
Differentiation of re-infection from relapse is very diffi-
cult; most articles use a combined risk or rate of re-infec-
tion and relapse [7,8], or estimated the relapse risk based
on the frequency of P. vivax during the non-transmission
season [9,10]. Although molecular epidemiology intro-
duced new methods to discriminate re-infection from
relapse, these methods are very expensive and, in many
cases, they could not address the question accurately [11-
13]. In French Guiana, there is a widespread belief that P.
vivax was of the 'tropical' type, which is characterized by
an early primary attack, followed by a short latent period
before appearance of frequent relapses during the next
year, but no published evidence from French Guiana or
elsewhere in South America supports this belief.
The study objectives were to determine the relapse pattern
of P. vivax using an alternative method and to propose a
simple classification to easily differentiate re-infections
from relapses.
Methods
This research was carried out in Camopi, an Amerindian
village (Wayampi and Emerillon) located in the Amazon
forest along the Oyapock River, which marks the eastern
border with Brazil. The incidence of malaria there is
around 40% [14]. A retrospective study using an open
cohort design was carried out with all Camopi children
born between January 1, 2001 and December 31, 2008.
The children came to the health center approximately
once a month, generally at the time of illness or for sys-
tematic visits (i.e. vaccination). Every six months, there is
a verification that all newborn children are included in the
cohort, that all children are present in the village, and that
all the malaria data is collected. Data for children for
whom follow-up by the health center had been inter-
rupted was right censored at the interruption date. It was
assumed that all malaria attacks were recorded at the local
health centre [15]. The Camopi health center ensures free
early diagnosis and treatment of malaria cases. Because of
the extreme isolation, no other health facilities (public or
private) are available in this part of the Amazonian forest.
The list of all clinical malaria episodes, their date of occur-
rence, Plasmodium species identification were made in
the Camopi health center by two physicians, two nurses,
and one Amerindian assistant. All thin blood smears were
first analysed in Camopi by a trained nurse and then
checked by the parasitological unit of Cayenne General
Hospital, the referent malaria center in French Guiana.
Malaria was defined as temperature > 38°C at the time of
consultation or fever within the past 48 hours associated
with Plasmodium asexual forms on a thin blood smear
(detection threshhold: 50 Plasmodium/μl). During the
study period, all confirmed cases of P. vivax received a
three-day treatment of chloroquine (total 25 mg/kg).
Cases with mixed infections and therapeutic treatment
failure (attack in the two weeks following the first attack
treated correctly) were excluded from the study. In
Camopi, treatment with a combination of primaquine
(14 days) and chloroquine (3 days) was initiated in 2005,
but only for P. vivax cases following a first relapse, which
did not affect analysis in this study. This prescription of
primaquine implies respecting French prescription rules:
systematic screening for G6PD deficiency (counter-indica-
tion if G6PD deficiency) and delivery as a nominal tem-
porary use authorization.
All parents were given an explanation and written consent
was obtained for the study. The study was reviewed and
approved by the Ethical Committee of Antilles-Guyane.
Two groups of patients were analysed. The first one
included the whole population of Camopi children born
between January 1, 2001 and December 31, 2008. It was
assumed that the first P. vivax attack after birth in this
group was due to a new infection. The second one
included only those who had had a primary attack due to
P. vivax. In this group, the secondary P. vivax attack occur-
ring more than two weeks after a correctly treated primary
attack was due to either re-infection or relapse. Therefore,
it was assumed that the difference between primary and
secondary attack rate of P. vivax could be an estimate of
the relapse rate. According to the above reasoning, the
yearly incidences and the monthly rates of attacks in these
groups were estimated using survival analysis methods.
Data were right censored by time of child departure from
village or death, or time to attack if attack was due to
another Plasmodium species. Monthly attack rates were
calculated by derivation of the survival curves. Monthly
relapse rates were then calculated by difference between
the secondary and primary attack rates. All statistical anal-
yses were conducted using R 2.7.1 and the package Epicalc
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Results
Between January 2001 and December 2008, 1,042
malaria attacks were recorded in Camopi in 325 children
born during this period, of which 319 (31%) were due to
P. falciparum, 689 (66%) to P. vivax, 21 (2%) to mixed
infections and 13 (1%) to P. malariae or Plasmodium sp.
One hundred and fifty one persons had their primary
attack with P. vivax and 106 had their two first attacks with
P. vivax. Annual incidence and survival time in the two
groups were synthesised in table 1. Under the working
hypothesis 0.12 relapses occurred each year per person
who had had a first attack caused by P. vivax. Using inci-
dences of each group, the proportion of relapses in the
whole secondary P. vivax attacks was estimated at 28%.
Figure 1 compares the monthly rate of first P. vivax attack
since birth and the monthly rate of secondary attack since
first P. vivax attack classified by the time to attack. The pat-
tern of changes in both groups was clearly distinct. The
rate of primary attack seemed to be constant and uniform
along the time and was approximately 0.03% per month
and 100 persons at risk. On the contrary, the rate of sec-
ondary attacks had a sharp peak during the three first
months following the first attack and reached a uniform
and constant level after four months comparable to the
rate of primary attacks. When relapse rate temporal trends
were computed according to the working hypothesis, P.
vivax relapses were shown to mainly occur during the first
three months after the primary attack. A survival curve for
relapses was computed. Thirty percent of children never
had a relapse, 42% had a relapse before the first month
after the primary attack, 59% before the second month
and 63% before the third month. After eight months the
probability to relapse was nil.
Discussion
This study showed that, in Camopi, the peak of relapses of
P. vivax occurred in the first three months after the first
attack. After that, most secondary attacks were mainly due
to a new P. vivax re-infection. These observations con-
firmed the assumption of a pure tropical pattern with a
short latent period for P. vivax relapses in French Guiana
(Chesson strain [17]). In India, the existence of both trop-
ical and temperate zone types of P. vivax characterized by
distinct incubation period for relapse were clearly sug-
gested [9].
The current biological methods to differentiate re-infec-
tions from relapses have their limits. This study suggests
that this simple alternative can estimate the relapse rate in
P. vivax infection indirectly. However, this method has its
own limitations. First, this method to estimate the relapse
rate cannot be used in areas where primaquine is associ-
ated to chloroquine to treat the first and the second
malaria attacks.
Second, it cannot differentiate the relapses from re-infec-
tions in individual patients; it estimates the overall relapse
rate in the population. It seems that this limitation can be
partially resolved by a simple arbitrary classification rule
inferred from the results ofthis study. At an individual
scale, before 90 days there is a strong probability that the
secondary attack is a relapse, after 90 days it is more prob-
able that the secondary attack is a re-infection. By positing
that the primary rate of infection is the same than the sec-
ondary rate of re-infection, it can be assumed that immu-
nity against P. vivax after the primary attack is negligible.
As shown elsewhere [18,19], this does not seem to be an
unreasonable hypothesis.
Third, similarly, because this study was based on the fol-
low-up of children from birth, the re-infection rate based
on the primary attack rate was under-estimated because of
the maternal protective immunity during the first 12
months after birth. However, this effect plays in the oppo-
site way of the previous bias and it didn't seem to influ-
ence significantly study results.
Conclusion
This study confirmed that the relapse pattern in Camopi
was compatible with the pattern observed with the P. vivax
Chesson (tropical) strain. In addition, due to the relapse
Table 1: Annual incidence rate$* and survival time of the primary and secondary P. vivax attack in the Camopi children population.
STUDIED 
POPULATION
NUMBER OF 
SUBJECTS
TIME AT 
RISK
INCIDENCE 
RATE
SURVIVAL TIME (YEAR) RELAPSE 
INCIDENCE 
RATE
25% 50% 75%
PRIMARY P. 
VIVAX 
ATTACKS
The Camopi 
Children population
325 571.76 0.31 1.23 2.33 4 0
SECONDARY P. 
VIVAX 
ATTACKS
Children having had 
a primary P. Vivax 
attack
151 100.42 0.43 0.76 2.14 3.58 0.12
$: Rate unit: attack/persons at risk/per year
*: Right censoring was used in survival analysisMalaria Journal 2009, 8:278 http://www.malariajournal.com/content/8/1/278
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rate time evolution, a simple arbitrary classification rule
could be constructed: before 90 days after the primary
attack, the secondary attack is a relapse; after 90 days it is
a re-infection. Adapted management of malaria cases
based on these results could be devised: systematic pre-
scription of primaquine for all relapses defined by this
three-month rule, despite the obligations of screening for
G6PD deficiency and administrative formalities involved
on French territories. These results could be used in
French Guiana and elsewhere in South America to dis-
criminate P. vivax relapses from re-infections.
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